BNTC
Benitec Biopharma Inc.
There isn't enough reported data to score BNTC yet.
BNTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
BNTC's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
BNTC PE Valuation
BNTC has no meaningful PE right now: it lost money over the past year.
BNTC Forward outlook
There aren't enough analyst estimates for BNTC to show an outlook.
BNTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.98 | +$0.28 |
BNTC is still losing money, but far less than before: $0.98 per share over the past year, against $62.37 at its worst in early 2020.
BNTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $54K | +13% |
| Q4 2022 | $14K | -44% |
| Q1 2022 | $48K | +4700% |
| Q4 2021 | $25K | +2400% |
| Q1 2021 | $1K | -97% |
| Q4 2020 | $1K | -99% |
| Q3 2020 | $55K | +64% |
BNTC's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -65000% | N/A |
| Q1 2023 | -8039% | -831 points |
| Q4 2022 | -40071% | -20731 points |
| Q1 2022 | -7208% | +372092 points |
| Q4 2021 | -19340% | +306560 points |
| Q2 2021 | -192750% | -185211 points |
| Q1 2021 | -379300% | -376558 points |
| Q4 2020 | -325900% | -322367 points |
BNTC's operating margin was −65000% last quarter, down 45660 points from the same quarter a year ago.
BNTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5M | +$3.2M |
| Q1 2026 | -$4.5M | -$1.4M |
| Q3 2025 | -$3.4M | +$1.2M |
| Q2 2025 | -$8.2M | -$4.9M |
| Q3 2024 | -$4.6M | -$9K |
| Q4 2023 | -$5.4M | +$478K |
| Q3 2023 | -$4.6M | -$532K |
| Q1 2023 | -$4M | -$607K |
BNTC has burned cash in almost every quarter: −$21M over the past year, against −$16M the year before.
BNTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +3.4M shares |
| 1 year | +28% | +10.8M shares |
| 3 years | +7634% | +48.7M shares |
| 5 years | +19499% | +49.1M shares |
BNTC has 49M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
BNTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2019 | -4.5x | Net Cash |
BNTC has more cash than debt.
BNTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 20.3 | Neutral |
BNTC's weekly RSI is 41 (neutral) and its Stochastic is 20 (neutral).
BNTC PE vs Healthcare Sector
BNTC has no meaningful PE right now: it lost money over the past year.
BNTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.95 | 1.6% above |
| 20 week MA | $11.1 | 18% below |
| 50 week MA | $11.5 | 21% below |
| 100 week MA | $12.3 | 26% below |
| 200 week MA | $8.98 | 1.2% above |
BNTC's trend is mixed: it's above two of its five weekly moving averages, and 1.2% above its 200-week average.
BNTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $116.5 | $52.5 | -55% |
| 2021 | $52.5 | $50.7 | -3.6% |
| 2022 | $50.7 | $2.94 | -94% |
| 2023 | $2.94 | $3.23 | +9.9% |
| 2024 | $3.23 | $12.0 | +272% |
| 2025 | $12.0 | $13.1 | +9.2% |
| 2026 YTD | $13.1 | $9.09 | -31% |
BNTC's yearly returns have swung widely, from +272% in 2024 to −94% in 2022. It's down 31% so far in 2026.